Akums Drugs and Pharmaceuticals Limited (NSE:AKUMS) defied analyst predictions to release its second-quarter results, which were ahead of market expectations. Akums Drugs and Pharmaceuticals delivered a significant beat with revenue hitting ₹13b and statutory EPS reaching ₹7.37, both beating estimates by more than 10%. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on Akums Drugs and Pharmaceuticals after the latest results.
After the latest results, the three analysts covering Akums Drugs and Pharmaceuticals are now predicting revenues of ₹50.2b in 2027. If met, this would reflect a credible 4.1% improvement in revenue compared to the last 12 months. Statutory earnings per share are predicted to grow 15% to ₹27.35. Yet prior to the latest earnings, the analysts had been anticipated revenues of ₹50.2b and earnings per share (EPS) of ₹27.35 in 2027. So it's pretty clear that, although the analysts have updated their estimates, there's been no major change in expectations for the business following the latest results.
See our latest analysis for Akums Drugs and Pharmaceuticals
The analysts reconfirmed their price target of ₹863, showing that the business is executing well and in line with expectations. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. There are some variant perceptions on Akums Drugs and Pharmaceuticals, with the most bullish analyst valuing it at ₹880 and the most bearish at ₹850 per share. The narrow spread of estimates could suggest that the business' future is relatively easy to value, or thatthe analysts have a strong view on its prospects.
Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. The analysts are definitely expecting Akums Drugs and Pharmaceuticals' growth to accelerate, with the forecast 8.3% annualised growth to the end of 2027 ranking favourably alongside historical growth of 4.0% per annum over the past three years. Compare this with other companies in the same industry, which are forecast to see revenue growth of 17% annually. So it's clear that despite the acceleration in growth, Akums Drugs and Pharmaceuticals is expected to grow meaningfully slower than the industry average.
The Bottom Line
The most obvious conclusion is that there's been no major change in the business' prospects in recent times, with the analysts holding their earnings forecasts steady, in line with previous estimates. Fortunately, the analysts also reconfirmed their revenue estimates, suggesting that it's tracking in line with expectations. Although our data does suggest that Akums Drugs and Pharmaceuticals' revenue is expected to perform worse than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.
Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. At Simply Wall St, we have a full range of analyst estimates for Akums Drugs and Pharmaceuticals going out to 2029, and you can see them free on our platform here..
You should always think about risks though. Case in point, we've spotted 1 warning sign for Akums Drugs and Pharmaceuticals you should be aware of.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.